

**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claim 1. (original) A therapeutic agent for glaucoma comprising a combination of a Rho kinase inhibitor and a prostaglandin.

Claim 2. (original) A therapeutic agent for glaucoma characterized in that it comprises a combination of a Rho kinase inhibitor and a prostaglandin, and they complement and/or enhance their actions each other.

Claim 3. (currently amended) The therapeutic agent for glaucoma as claimed in claim 1 ~~or~~ 2, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Claim 4. (currently amended) The therapeutic agent for glaucoma as claimed in claim 1 ~~or~~ 2, wherein the

prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 5. (original) A method of treating glaucoma comprising administering effective amounts of a Rho kinase inhibitor in combination with a prostaglandin to a patient.

Claim 6. (original) A method of treating glaucoma characterized by administering effective amounts of a Rho kinase inhibitor in combination with a prostaglandin to a patient, thereby they complementing and/or enhancing their actions each other.

Claim 7. (currently amended) The method of treating glaucoma as claimed in claim 5 ~~or 6~~, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Claim 8. (currently amended) The method of treating glaucoma as claimed in claim 5 ~~or 6~~, wherein the

prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 9. (cancelled)

Claim 10. (cancelled)

Claim 11. (cancelled)

Claim 12. (cancelled)

Claim 13. (new) The therapeutic agent for glaucoma as claimed in claim 2, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Claim 14. (new) The therapeutic agent for glaucoma as claimed in claim 2, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 15. (new) The therapeutic agent for glaucoma as claimed in claim 3, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 16. (new) The therapeutic agent for glaucoma as claimed in claim 13, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 17. (new) The method of treating glaucoma as claimed in claim 6, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Claim 18. (new) The method of treating glaucoma as claimed in claim 6, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 19. (new) The method of treating glaucoma as

claimed in claim 7, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 20. (new) The method of treating glaucoma as claimed in claim 17, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.